v3.22.2.2
STOCKHOLDERS’ EQUITY (Tables)
6 Months Ended
Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF RESTRICTED STOCK AWARDS

A summary of the Company’s restricted stock unit awards for the period ended September 30, 2022 is as follows:

 

  

Number Of

Shares

  

Weighted

Average Grant

Date Fair

Value

 
         
Unvested as of April 1, 2022   949,600    6.92 
Granted   -    - 
Vested   -    - 
Forfeited   -    - 
Unvested as of September 30, 2022   949,600   $6.92 
SCHEDULE OF FAIR VALUE OF OPTION

The following was utilized to calculate the fair value of options on the date of grant:

 

   

September 30,

2022

   

September 30,

2021

 
Risk-free interest rate     2.5 - 3.7 %     0.1 %
Expected volatility (Beyond Air)     87.4 - 89.1 %     90.390.5 %
Expected volatility (Beyond Cancer)     104.7106.7 %     n/a  
Dividend yield     0 %     0 %
Expected terms (in years)     6.25       6.25  
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE

The following summarizes the components of stock-based compensation expense which include stock options and restricted stock for the three and six months ended September 30, 2022 and September 30, 2021, respectively:

 

(in thousands)  2022   2021   2022   2021 
   Three Months Ended   Six Months Ended 
   September 30,   September 30, 
(in thousands)  2022   2021   2022   2021 
Research and development  $1,002   $379   $1,957   $744 
General and administrative   3,713    776    7,381    1,627 
Total stock-based compensation expense  $4,714   $1,155   $9,338   $2,371 
SUMMARY OF COMPANY’S OUTSTANDING WARRANTS

A summary of the Company’s outstanding warrants as of September 30, 2022 is as follows:

 

Warrant Holders 

Number Of

Warrants

  

Exercise

Price

  

Intrinsic Value

(in thousands)

  

Date of

Expiration

Third-party license agreement   208,333   $4.80   $550   January 2024
March 2020 loan   172,187   $7.26    31   March 2025
NitricGen Agreement   80,000   $6.90    43   January 2028
Total   460,520   $6.08   $624    
2013 Beyond Air Equity Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF OPTION ACTIVITY

A summary of the change in options for the six months ended September 30, 2022, is as follows:

 

  

Number Of

Options

  

Weighted

Average

Exercise

Price

Options

  

Weighted

Average

Remaining

Contractual

Life-

Options

  

Aggregate

Intrinsic

Value

(in thousands)

 
                 
Options outstanding as of April 1, 2022   5,508,631   $5.60    8.1   $6,831 
Granted   116,500    7.95    -    - 
Exercised   (15,000)   5.21    -    - 
Forfeited   (28,500)   5.88    -    - 
Outstanding as of September 30, 2022   5,581,631   $5.65    7.6   $10,565 
Exercisable as of September 30, 2022   2,548,881   $4.77    6.3   $6,879 
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF OPTION ACTIVITY

 

  

Number Of

Options

  

Weighted

Average

Exercise

Price–-

Options

  

Weighted

Average

Remaining

Contractual

Life-

Options

  

Aggregate

Intrinsic

Value

(thousands)

 
                 
Options outstanding as of April 1, 2022   1,763,500   $2.76    9.3   $12,768 
Granted   89,000    10.00    9.6    - 
Exercise   -    -    -    - 
Forfeited   (10,000)   10,00    9.5    - 
Outstanding as of September 30, 2022   1,842,500   $3.07    9.3   $12,759 
Exercisable as of September 30, 2022   -   $-    -   $-